Shopping Cart
- Remove All
- Your shopping cart is currently empty
BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19 nM and 22 nM, respectively.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | $1,240 | 7-10 days | |
25 mg | $2,130 | 7-10 days |
Description | BPR1K871, a preclinical development candidate for anti-cancer therapy [1], is a potent, selective dual inhibitor targeting FLT3 and AURKA, with IC50 values of 19 nM and 22 nM, respectively. |
Targets&IC50 | AURKA:22 nM , FLT3:19 nM |
In vitro | BPR1K871 demonstrates strong anti-proliferative effects on MOLM-13 and MV4-11 AML cells, achieving an EC50 of approximately 5 nM [1]. |
In vivo | BPR1K871, a multi-kinase inhibitor, is utilized for the treatment of acute myeloid leukemia (AML) and solid tumors [1]. |
Alias | DBPR114 |
Molecular Weight | 526.05 |
Formula | C25H28ClN7O2S |
Cas No. | 2443767-35-7 |
Relative Density. | 1.387 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 125 mg/mL (237.62 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.